|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0031669,
umls-concept:C0044602,
umls-concept:C0285761,
umls-concept:C0879396,
umls-concept:C0919281,
umls-concept:C1122962,
umls-concept:C1150481,
umls-concept:C1368105,
umls-concept:C1415793,
umls-concept:C1451005,
umls-concept:C1622501,
umls-concept:C1704259,
umls-concept:C1705325,
umls-concept:C1705987
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-12-17
|
|
pubmed:abstractText |
Expression of epidermal growth factor receptor (EGFR) by human breast cancer tissues is associated with poor clinical response. The EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib ('Iressa', ZD1839), is a leading example of a molecular targeted agent, and has an anti-proliferative effect on various cancer cells. But the details of the anti-cancer effect and mechanism have not been elucidated. We studied the anti-cancer effect of gefitinib in breast cancer cell lines and the intracellular pathway downstream of EGFR associated with cell migration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1340-6868
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
367-73
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15604992-Antineoplastic Agents,
pubmed-meshheading:15604992-Blotting, Western,
pubmed-meshheading:15604992-Breast Neoplasms,
pubmed-meshheading:15604992-Cell Line, Tumor,
pubmed-meshheading:15604992-Cell Movement,
pubmed-meshheading:15604992-Epidermal Growth Factor,
pubmed-meshheading:15604992-Female,
pubmed-meshheading:15604992-Humans,
pubmed-meshheading:15604992-Neoplasm Invasiveness,
pubmed-meshheading:15604992-Phosphatidylinositol 3-Kinases,
pubmed-meshheading:15604992-Protein Kinase Inhibitors,
pubmed-meshheading:15604992-Quinazolines,
pubmed-meshheading:15604992-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15604992-Type C Phospholipases
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
|
|
pubmed:affiliation |
Department of Surgery II, University of Okayama, 1-5-2 Shikata-cho, Okayama 700-8558, Japan. tada99@mint.ocn.ne.jp
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
